Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 18 January 2022, 13:00 HKT/SGT
Share:
    

Source: Avance Clinical
Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022

ADELAIDE, AUS, Jan 18, 2022 - (ACN Newswire) - Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m.


Avance Clinical is taking meetings with biotechs to discuss the benefits of conducting trials in Australia, including no IND requirement and an attractive 43.5% rebate, at Biotech Showcase 2022 via PartneringOne.

Connect with the Avance Clinical Team here https://www.avancecro.com/contact-us/

Download the APAC clinical trial advantages report from Frost & Sullivan here
https://www.avancecro.com/download-apac-clinical-trial-report-frost-sullivan/

Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry.

The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies.

Avance Clinical's CEO Yvonne Lungershausen said: "With the support of Riverside and its powerful global footprint and deep healthcare experience, Avance Clinical will execute on its regional and international expansion plans organically and via acquisitions."

"We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector," said Lungershausen.

Leading analyst firm Frost & Sullivan says the Asia-Pacific's CRO market value, currently at $6.01 billion, is estimated to reach nearly $11.04 billion in 2026, growing at a compound annual rate of 12.2%.

Avance Clinical has more than 170 specialist clinical staff and has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.

Riverside Partner Nick Speer said: "We were highly attracted to Avance's leading management team who have secured blue-chip customers from across the globe, providing them with world-class services. Riverside brings decades of global life sciences experience, which we will leverage to further support Avance's growth objectives, with a particular focus on North America and Asia."

"Australia is the global destination of choice for early phase and increasingly later phase clinical trials. We intend to work with Yvonne and her team to further accelerate the growth of Avance," said Speer.

"Global sponsors are attracted to Australia and Avance Clinical for trial quality and efficient timeframes. Study start-up can be achieved in 5-6 weeks with the right CRO, leveraging the lack of IND requirement and the R&D tax rebate. This means clients can get into the clinic up to a year earlier than anywhere else in the world, saving significant associated costs while enabling life-saving treatments to reach market sooner."

Avance Clinical was advised by Allier Capital and Riverside by Lazard Australia.

Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/

For more information about the benefits of running your next study with Avance Clinical contact us: https://www.avancecro.com/contact-us/

About Avance Clinical

Avance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.

Frost & Sullivan awards

Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for 24 years.

Pre-clinical through to Phase 1 and 2

Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.

With experience across more than 105 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

Technology

Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of the technology partners.

About The Riverside Company

The Riverside Company is a global private equity firm focused on investing in growing businesses valued at up to $400 million. Since its founding in 1988, Riverside has made more than 800 investments. The firm's international private equity and structured capital portfolios include more than 140 companies.

Media Contacts:
Avance Clinical
Chris Thompson
media@avancecro.com

The Riverside Company
Holly Mueller
hmueller@riversidecompany.com


Topic: Press release summary
Source: Avance Clinical

Sectors: BioTech, Healthcare & Pharm, Clinical Trials
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Avance Clinical
Apr 19, 2022 10:00 HKT/SGT
Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 - Best Contract Research Organization in APAC
Mar 31, 2022 15:00 HKT/SGT
Avance Clinical Announces New Office Opening in Melbourne
Mar 2, 2022 15:00 HKT/SGT
Avance Clinical Announces New Office Opening in Sydney
Oct 19, 2021 15:00 HKT/SGT
Avance Clinical Client News: XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain
Aug 10, 2021 14:00 HKT/SGT
Avance Clinical Awarded Frost & Sullivan 2021 Asia-Pacific CRO Best Practices Award for Customer Value Leadership
July 9, 2021 20:00 HKT/SGT
Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia
June 28, 2021 14:00 HKT/SGT
Avance Clinical Appoints Asia Biotech Specialist to Support APAC Growth
June 4, 2021 08:00 HKT/SGT
Avance Clinical's USA Biotech Survey Finds 21% Not Aware Australian Clinical Data is Accepted by the FDA and Other Major Regulatory Authorities
May 27, 2021 10:00 HKT/SGT
Avance Clinical Releases Industry Survey Results at BIO Korea 2021
May 7, 2021 00:00 HKT/SGT
Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand
More news >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: